On Monday, Castle Biosciences received a positive adjustment to its Relative Strength (RS) Rating, from 80 to 85.
This proprietary rating identifies technical performance by showing how a stock's price action over the last 52 weeks compares to that of the other stocks in our database.
Over 100 years of market history reveals that the best-performing stocks often have an 80 or higher RS Rating as they begin their biggest runs.
Risk Management In The Stock Market: How Much Money To Invest Now
Castle Biosciences is now considered extended and out of buy range after clearing a 25.91 buy point in a first-stage consolidation. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average.
Castle Biosciences reported 0% earnings growth in the latest quarterly report. Revenue rose 40%.
The company holds the No. 6 rank among its peers in the Medical-Services industry group. Hims & Hers Health, Guardian Pharmacy Svcs and Castle Biosciences are among the top 5 highly rated stocks within the group.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
